1
/
of
0
FDA Drug Approval, A208891, WIXELA INHUB
FDA Drug Approval, A208891, WIXELA INHUB
Regular price
$89.00 USD
Regular price
Sale price
$89.00 USD
Unit price
/
per
ANDA: 208891
Company: MYLAN
Drug Name: WIXELA INHUB
Active Ingredients: FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE
Strength: 0.5MG/INH;EQ 0.05MG BASE/INH
Dosage Form/Route: POWDER;INHALATION
Action Date: 01/30/2019
Marketing Status: Prescription
Submission Classification: ORIG-1 TE Code: AB
Company: MYLAN
Drug Name: WIXELA INHUB
Active Ingredients: FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE
Strength: 0.5MG/INH;EQ 0.05MG BASE/INH
Dosage Form/Route: POWDER;INHALATION
Action Date: 01/30/2019
Marketing Status: Prescription
Submission Classification: ORIG-1 TE Code: AB
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.
View full details